The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Evolution of drug delivery systems: From 1950 to 2020 and beyond
Open accessAbstract
Modern drug delivery technology began in 1952 with the advent of the Spansule® sustained-release capsule technology, which can deliver a drug for 12 hours after oral administration through an initial immediate dose followed by the remaining released gradually. Until the 1980s, oral and transdermal formulations providing therapeutic durations up to 24 hours for small molecules dominated the drug delivery field and the market. The introduction of Lupron Depot® in 1989 opened the door for long-acting injectables and implantables, extending the drug delivery duration from days to months and occasionally years. Notably, the new technologies allowed long-term delivery of peptide and protein drugs, although limited to parenteral administration. The introduction of the first PEGylated protein, Adagen®, in 1990 marked the new era of PEGylation, resulting in Doxil® (doxorubicin in PEGylated liposome) in 1995, Movantik (PEGylated naloxone - naloxegol) in 2014, and Onpattro® (Patisiran - siRNA in PEGylated lipid nanoparticle) in 2018. Drug-polymer complexes were introduced, e.g., InFed® (iron-dextran complex injection) in 1974 and Abraxane® (paclitaxel-albumin complex) in 2005. In 2000, both Mylotarg™ (antibody-drug conjugate – gemtuzumab ozogamicin) and Rapamune® (sirolimus nanocrystal formulation) were introduced. The year 2000 also marked the launching of the National Nanotechnology Initiative by the U.S. government, which was soon followed by the rest of the world. Extensive work on nanomedicine, particularly formulations designed to escape from endosomes after being taken by tumor cells, along with PEGylation technology, ultimately resulted in the timely development of lipid nanoparticle formulations for COVID-19 vaccine delivery in 2020. While the advances in drug delivery technologies for the last seven decades are breathtaking, they are only the tip of an iceberg of technologies that have yet to be utilized in an approved formulation or even to be discovered. As life expectancy continues to increase, more people require long-term care for various diseases. Filling the current and future unmet needs requires innovative drug delivery technologies to overcome age-old familiar hurdles, e.g., improving water-solubility of poorly soluble drugs, overcoming biological barriers, and developing more efficient long-acting depot formulations. The lessons learned from the past are essential assets for developing future drug delivery technologies implemented into products. As the development of COVID-19 vaccines demonstrated, meeting the unforeseen crisis of the uncertain future requires continuous cumulation of failures, knowledge, and technologies. Conscious efforts of supporting diversified research topics in the drug delivery field are urgently needed more than ever.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 1×
“mRNA vaccines for Zika virus and cancer were already in human studies when COVID-19 started [160,161], and the robustness and versatility of mRNA-based vaccine technology allowed the fast production of COVID-19 vaccines.”
BackgroundAdherence to Long‐Term Therapies: Evidence for Action
Burkhart, P. V., & Sabaté, E. (2003) · Journal of Nursing Scholarship · doi:10.1111/j.1547-5069.2003.tb00001.x · Cited by 2,526
Liposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,156
Targeted drug delivery to tumors: Myths, reality and possibility
Bae, Y. H., & Park, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.001 · Cited by 1,935
Self-citationBangham, A. D., & Horne, R. W. (1964) · Journal of Molecular Biology · doi:10.1016/s0022-2836(64)80115-7 · Cited by 1,809
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability
Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120586 · Cited by 1,566
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Research works printed but not linked: 12
- Ullyot, 2000, The metamorpohsis of Smith-Kline & French Laboratories to Smith Kline Beecham: 1925-1998, Bull. Hist. Chem., 25, 16, 10.70359/bhc2000v025p016 · doi:10.70359/bhc2000v025p016
- Liu, 1984, Comparative release of phenylpropanolamine HCl from long-acting appetite suppressant products: Acutrim vs, Dexatrim. Drug Develop. and Indus. Pharm., 10, 1639, 10.3109/03639048409039072 · doi:10.3109/03639048409039072
- Davis, 1979, Non-immunogenic polypeptides, 4, 337
- Ellory, 2010, AD Bangham (1922-2010), Physiology News, 79, 55
- Wu, 2020, Drug development through modification of small molecular drugs with Monodisperse poly(ethylene glycol)s, Org. Process. Res. Dev., 24, 1364, 10.1021/acs.oprd.0c00273 · doi:10.1021/acs.oprd.0c00273
- Lawrence, 1998, Development and comparison of iron dextran products, PDA J. Pharm. Sci. Technol., 52, 190
- Morrow, 2010, DNA drugs come of age, Sci. Am., 49
- Lindsley, 2011, The top prescription drugs of 2010 in the United States: antipsychotics show strong growth, ACS Chem. Neurosci., 2, 276, 10.1021/cn200050c · doi:10.1021/cn200050c
- Israeli, 1998, Paul Ehrlich's ingredients for success, Lancet, 352, 1712, 10.1016/S0140-6736(05)61497-3 · doi:10.1016/s0140-6736(05)61497-3
- FDA/CDER, 2000, Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification, System
- Chaplin, 2020, Rybelsus: an oral formulation of the GLP-1 agonist semaglutide, Prescriber, 31, 32
- Li, 2019, Fabrication of gradient porous microneedle array by modified hot embossing for transdermal drug delivery, Mater. Sci. Eng. C, 96, 576, 10.1016/j.msec.2018.11.074 · doi:10.1016/j.msec.2018.11.074
Cited by
Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment
Liu, R., Luo, C., Pang, Z., Zhang, J., Ruan, S., Wu, M., Wang, L., Sun, T., Li, N., Han, L., et al. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.05.032 · Cited by 516
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Desai, N., Rana, D., Patel, M., Bajwa, N., Prasad, R., & Vora, L. K. (2025) · Small · doi:10.1002/smll.202502315 · Cited by 295
Liu, J., Liu, J., Mu, W., Ma, Q., Zhai, X., Jin, B., Liu, Y., & Zhang, N. (2024) · ACS Nano · doi:10.1021/acsnano.4c02380 · Cited by 74
Bi, Y., Chen, J., Li, Q., Li, Y., Zhang, L., Zhida, L., Yuan, F., & Zhang, R. (2024) · iScience · doi:10.1016/j.isci.2024.108833 · Cited by 24
Metadata
- Authors
- Park, H., Otte, A., & Park, K.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 342
- Pages
- 53-65
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W4200575452
- Cited by
- 475
- References
- 121
- FWCI
- 20.60
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- National Institute on Drug Abuse
- Ralph W. and Grace M. Showalter Research Trust Fund
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evolution of drug delivery systems: From 1950 to 2020 and beyond. https://app.cochat.ai/papers/10.1016/j.jconrel.2021.12.030
- The paper
- Park, H., Otte, A., & Park, K. (2022). Evolution of drug delivery systems: From 1950 to 2020 and beyond. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2021.12.030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.